Select Page



MindImmune Therapeutics Appoints Brad Margus and Robert Michael Poole, MD FACP, to its Board of Directors

MindImmune Therapeutics appointmens Brad Margus and Robert Michael Poole, MD, FACP to its Board of Directors, with Mr. Margus assuming the role of Board Chair.

MindImmune Therapeutics Announces
$12.4 million Series A Financing

Investors participating in the round include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures (an affiliate of the Slater Technology Fund) and several private investors.